Results 21 to 30 of about 124,093 (287)

Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels [PDF]

open access: yes, 2007
Disrupted-in-schizophrenia 1 (DISC1) is a genetic susceptibility factor for schizophrenia and related severe psychiatric conditions. DISC1 is a multifunctional scaffold protein that is able to interact with several proteins, including the independently ...
Millar, J.K.   +14 more
core   +1 more source

Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss [PDF]

open access: yes, 2013
Phosphodiesterase type 5 Inhibitors, such as sildenafil, vardenafil and tadalafil have been increasingly used today and some of the users have developed sudden sensorineural hearing loss.ObjectiveTo present two patients with sudden deafness developed ...
Bahmad Jr,Fayez   +6 more
core   +1 more source

Phosphodiesterase 5 inhibitors: are they cardioprotective? [PDF]

open access: yesCardiovascular Research, 2009
A growing body of animal studies provides evidence for potential cardioprotective effects of inhibitors of the enzyme phosphodiesterase isoform 5. Infarct size reduction by administration of phosphodiesterase 5 inhibitors was described in various experimental models of ischaemia and reperfusion.
Thorsten, Reffelmann, Robert A, Kloner
openaire   +2 more sources

A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool

open access: yesJournal of Research in Pharmacy Practice, 2015
Cyclic nucleotide phosphodiesterases (PDEs) are known as a super-family of enzymes which catalyze the metabolism of the intracellular cyclic nucleotides, cyclic-3',5'-adenosine monophosphate (cAMP), and cyclic-3',5'-guanosine monophosphate that are ...
Nahid Eskandari   +5 more
doaj   +1 more source

Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study

open access: yesPulmonary Circulation, 2020
Phosphodiesterase-5 inhibitors are commonly used in pulmonary arterial hypertension but, as suggested by the RESPITE study, phosphodiesterase-5 inhibitor therapy (mono-/combination) does not always have a satisfactory treatment effect.
Clara Hjalmarsson   +8 more
doaj   +1 more source

Effect of phosphodiesterase-5 inhibitor on hearing

open access: yesThe Journal of Laryngology & Otology, 2009
AbstractObjective:Following a report of sudden hearing loss in a patient taking phosphodiesterase type 5 inhibitor, and a Food and Drug Administration announcement concerning this class of drugs, a study was planned to investigate if ototoxicity occurs in patients using phosphodiesterase 5 inhibitor for erectile dysfunction.Methods:Eighteen patients ...
Okuyucu, S.   +4 more
openaire   +2 more sources

Phenanthrenes from as Novel Phosphodiesterase-5 Inhibitors

open access: yesNatural Product Communications, 2017
Phosphodiesterase 5 (PDE5) inhibitors can be used for the treatment of erectile dysfunction and pulmonary hypertension. In order to search for new leads of PDE5 inhibitors, we investigated the chemical constituents of the tubers of Eulophia macrobulbon ...
Prapapan Temkitthawon   +5 more
doaj   +1 more source

Antioxidant effects of phosphodiesterase-5 inhibitors: reply [PDF]

open access: yesCardiovascular Research, 2013
We thank Dr. Tanus-Santos for his interest in our study.1 The study by Muniz et al .2 found that erectile dysfunction patients with the lowest levels of endogenous nitric oxide (NO) have the best responses to the phosphodiesterase-5 (PDE5) inhibitor sildenafil.
Rui, Zhang, Zhi-Cheng, Jing
openaire   +2 more sources

Portopulmonary hypertension practice patterns after liver transplantation

open access: yesLiver Transplantation, EarlyView., 2022
Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose   +3 more
wiley   +1 more source

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy

open access: yes, 2010
Mitchell S Buckley1, Robin L Staib1, Laura M Wicks1, Jeremy P Feldman21Department of Pharmacy, Banner Good Samaritan Medical Center, and 2Arizona Pulmonary Specialists Ltd, Phoenix, Arizona, USAAbstract: Pulmonary arterial hypertension (PAH) is a ...
null Robin Staib   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy